Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MegaPro Biomedical CoROCO:6827 -1.83%33 Return-on-Tangible-Equity is -54.50% as of Dec. 2025. GuruFocus rates ROCO:6827 with a GF Score™ of 33/100. Among 1,200 Biotechnology companies, MegaPro Biomedical Co ranks worse than 60.08% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MegaPro Biomedical Co's annualized net income for the quarter that ended in Dec. 2025 was NT$-104.33 Mil. MegaPro Biomedical Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$191.42 Mil. Therefore, MegaPro Biomedical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -54.50%.
The historical rank and industry rank for MegaPro Biomedical Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:6827'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -72.94 Med: -44.33 Max: -29.87
Current: -61.83
During the past 8 years, MegaPro Biomedical Co's highest Return-on-Tangible-Equity was -29.87%. The lowest was -72.94%. And the median was -44.33%.
ROCO:6827's Return-on-Tangible-Equity is ranked worse than 60.08% of 1200
companies
in the Biotechnology industry
Industry Median: -42.305
vs ROCO:6827: -61.83
MegaPro Biomedical Co (ROCO:6827) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MegaPro Biomedical Co Return-on-Tangible-Equity Related Terms
MegaPro Biomedical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MegaPro Biomedical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MegaPro Biomedical Co Return-on-Tangible-Equity Chart
ROCO:6827 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, MegaPro Biomedical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MegaPro Biomedical Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MegaPro Biomedical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MegaPro Biomedical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -54.50% mean?
MegaPro Biomedical Co (ROCO:6827) has a Return-on-Tangible-Equity of -54.50% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MegaPro Biomedical Co and its competitors. According to the industry distribution chart, MegaPro Biomedical Co ranks #721 out of 1200 companies in the Biotechnology industry, placing it in the top 60.1%.
Is MegaPro Biomedical Co's Return-on-Tangible-Equity too high?
MegaPro Biomedical Co's current Return-on-Tangible-Equity is -54.50%. Based on the distribution chart, MegaPro Biomedical Co ranks #721 out of 1200 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MegaPro Biomedical Co has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MegaPro Biomedical Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MegaPro Biomedical Co ranks #721 out of 1200 companies for Return-on-Tangible-Equity. This places MegaPro Biomedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MegaPro Biomedical Co and its competitors. MegaPro Biomedical Co's current Return-on-Tangible-Equity is -54.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MegaPro Biomedical Co stock overvalued right now?
MegaPro Biomedical Co (ROCO:6827) has a current Return-on-Tangible-Equity of -54.50%. The current Return-on-Tangible-Equity is -54.50%. MegaPro Biomedical Co's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MegaPro Biomedical Co (ROCO:6827), the current Return-on-Tangible-Equity is -54.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MegaPro Biomedical Co Ltd is a nanomedicine development company. The Company's only reportable operating segment is the Drug Application Development segment, which is engaged in the development of nano-iron oxide IOP drugs.
33GF Score
Get the complete analysis for ROCO:6827
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6827 has been successfully added to your 
